Isotretinoin Does Not Prevent Basal Cell Carcinoma

Abstract

The purpose of this editorial is twofold. First, we would like to bring the results of a recently completed therapeutic trial to the attention ofthe practicing clinician and, second, to point out the pitfalls by which therapeutic regimens gain widespread "acceptance." This prospective, double-blind, multicenter clinical trial, isotretinoin-basal cell carcinoma prevention study (ISO-BCC Study) conducted by the National Cancer Institute, Bethesda, Md, has determined that, despite preliminary indications to the contrary, oral isotretinoin was not effective in preventing the development of basal cell carcinomas (BCCs) in a population

Isotretinoin – unapproved indications/uses and dosage: a physician's reference

“…They categorically denied its effectiveness in preventing/reducing the occurrence of basal cell carcinoma, but also warned about significant adverse reactions during such therapies. The same views were later expressed by Robinson and Salasche 53 …”

Isotretinoin – unapproved indications/uses and dosage: a physician's reference

“…They categorically denied its effectiveness in preventing/reducing the occurrence of basal cell carcinoma, but also warned about significant adverse reactions during such therapies. The same views were later expressed by Robinson and Salasche 53 …”

Isotretinoin – unapproved indications/uses and dosage: a physician's reference

“…They categorically denied its effectiveness in preventing/reducing the occurrence of basal cell carcinoma, but also warned about significant adverse reactions during such therapies. The same views were later expressed by Robinson and Salasche 53 …”

Isotretinoin – unapproved indications/uses and dosage: a physician's reference

“…They categorically denied its effectiveness in preventing/reducing the occurrence of basal cell carcinoma, but also warned about significant adverse reactions during such therapies. The same views were later expressed by Robinson and Salasche 53 …”